The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients
Authors:
- Lisheng LiuLLLisheng Liu
- Yuqing ZhangYZYuqing Zhang
- Guozhang LiuGLGuozhang Liu
- Wei LiWLWei Li
- Xuezhong ZhangXZXuezhong Zhang
- Alberto ZanchettiAZAlberto Zanchetti
- 1 December 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 23 (12) , 2157-2172
Abstract
To compare the incidence of stroke and other cardiovascular events in hypertensive patients receiving a low-dose diuretic and low-dose calcium antagonist combination with those receiving low-dose diuretic monotherapy, and assess the effects of a small blood pressure difference at achieved levels lower than those achieved in previous placebo-controlled trials. The Felodipine Event Reduction (FEVER) trial was an investigator-designed, prospective, multicentre, double-blind, randomized, placebo-controlled, parallel group trial. It enrolled 9800 Chinese patients, of either sex, aged 50–79 years, with one or two additional cardiovascular risk factors or disease, whose blood pressure, 6 weeks after switching from previous antihypertensive therapy to low-dose (12.5 mg a day) hydrochlorothiazide, was in the range 140–180 mmHg (systolic) or 90–100 mmHg (diastolic). These patients were randomly assigned either to low-dose felodipine extended release or placebo, and followed at 3-month intervals for an average of 40 months. The intention-to-treat analysis included 9711 randomly selected patients with only 30 (0.3%) lost to follow-up. A total of 31 842 patient-years of follow-up were accumulated, with 85.9% of patients remaining on blinded randomized treatment. Add-on therapy was given to 33.9% of the hydrochlorothiazide–felodipine patients and to 42.3% of the hydrochlorothiazide–placebo patients. In the felodipine group, systolic blood pressure (SBP)/diastolic blood pressure (DBP) decreased (from randomization to study end) from 154.2/91.0 to 137.3/82.5 mmHg, and in the placebo group from 154.4/91.3 to 142.5/85.0 mmHg, with an average difference throughout the trial of 4.2/2.1 mmHg. In the felodipine group, the primary endpoint (fatal and non-fatal stroke) was reduced by 27% (P = 0.001). Among secondary endpoints, all cardiovascular events were reduced by 27% (P < 0.001), all cardiac events by 35% (P = 0.012), death by any cause by 31% (P = 0.006), coronary events by 32% (P = 0.024), heart failure by 30% (P = 0.239), cardiovascular death by 33% (P = 0.019), cancer by 36% (P = 0.017) in the felodipine group. No significant differences were found in new-onset diabetes. Both treatments were very well tolerated. In moderately complicated hypertensive patients from China even a difference in SBP/DBP as small as 4/2 mmHg, such as that induced by adding low-dose felodipine to low-dose hydrochlorothiazide, is associated with very substantial reductions in the incidence of most types of cardiovascular events. As the SBP achieved in the felodipine group was below the recommended goal of less than 140 mmHg, and SBP in the placebo group was slightly above that level, FEVER provides the required evidence in support of the guidelines recommended goal, even for a hypertensive population not entirely consisting of patients with diabetes or previous cardiovascular events.Keywords
This publication has 29 references indexed in Scilit:
- Evidence-based medicine in hypertension: what type of evidence?Journal Of Hypertension, 2005
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertensionJournal Of Hypertension, 2003
- 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*Journal Of Hypertension, 2003
- The Study on Cognition and Prognosis in the Elderly (SCOPE)Journal Of Hypertension, 2003
- Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profilesJournal Of Hypertension, 2003
- Blood pressure and cardiovascular disease in the Asia Pacific regionJournal Of Hypertension, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertensionJournal Of Hypertension, 1998